Literature DB >> 24120089

Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.

Katia Donadello1, Sabino Scolletta1, Fabio Silvio Taccone1, Cecilia Covajes1, Cristina Santonocito1, Diego Orbegozo Cortes1, Daiva Grazulyte1, Leonardo Gottin2, Jean-Louis Vincent3.   

Abstract

PURPOSE: The aim of this study was to assess the role of blood soluble urokinase-type plasminogen activator receptor (suPAR) levels in the diagnosis and prognostication of sepsis in critically ill patients.
METHODS: Serum suPAR levels were measured prospectively in adult intensive care unit (ICU) patients on admission and then daily until ICU discharge (maximum of 14 days) using an enzyme-linked immunosorbent assay kit. Normal levels were established in 31 healthy controls.
RESULTS: We included 258 patients (161 men); median admission Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores were 17 (9-23) and 6 (3-9), respectively. The mortality rate was 13.6%. Sepsis was diagnosed on admission in 94 patients (36%), of whom 23 had severe sepsis and 49 had septic shock. On admission, septic patients had higher suPAR levels than did nonseptic patients (8.9 [5.9-12.7] vs 3.7 [2.7-5.4] ng/mL), but the predictive value of suPAR for diagnosing sepsis was weaker than that of C-reactive protein. During the week after ICU admission, serum suPAR concentrations correlated with Sequential Organ Failure Assessment scores over time. High suPAR levels on admission were a strong independent predictor for ICU and 28-day mortality. In the global population, a suPAR level higher than 6.15 ng/mL had 66% sensitivity and 64% specificity for prediction of ICU mortality, with a receiver operating characteristic area under the curve of 0.726 (95% confidence interval, 0.645-0.808).
CONCLUSIONS: In ICU patients, serum suPAR concentrations have limited use for identifying sepsis, but their time course correlated with the degree of organ dysfunction, and they have prognostic value in septic and nonseptic populations.
© 2013.

Entities:  

Keywords:  Biomarker; CRP; Intensive care; Mortality; Organ dysfunction

Mesh:

Substances:

Year:  2013        PMID: 24120089     DOI: 10.1016/j.jcrc.2013.08.005

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  33 in total

1.  Chromogranin A levels and mortality in patients with severe sepsis.

Authors:  Chih-Hsin Hsu; Luis F Reyes; Carlos J Orihuela; Ricardo Buitrago; Antonio Anzueto; Nilam J Soni; Stephanie Levine; Jay Peters; Cecilia A Hinojosa; Stefano Aliberti; Oriol Sibila; Alejandro Rodriguez; James D Chalmers; Ignacio Martin-Loeches; Jose Bordon; Jose Blanquer; Francisco Sanz; Pedro J Marcos; Jordi Rello; Jordi Solé-Violán; Marcos I Restrepo
Journal:  Biomarkers       Date:  2015-07-08       Impact factor: 2.658

Review 2.  Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Authors:  Dubravka Kojic; Benedikt H Siegler; Florian Uhle; Christoph Lichtenstern; Peter P Nawroth; Markus A Weigand; Stefan Hofer; Thorsten Brenner
Journal:  World J Exp Med       Date:  2015-05-20

3.  Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.

Authors:  Zhaoyang Peng; Jianhua Mao; Xuejun Chen; Fengqing Cai; Weizhong Gu; Haidong Fu; Huijun Shen; Jingjing Wang; Xia Jin; Xiujuan Zhu; Aimin Liu; Qiang Shu; Lizhong Du
Journal:  Pediatr Nephrol       Date:  2014-07-18       Impact factor: 3.714

Review 4.  Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment.

Authors:  Mary Sandquist; Hector R Wong
Journal:  Expert Rev Clin Immunol       Date:  2014-08-21       Impact factor: 4.473

Review 5.  Sepsis: in search of cure.

Authors:  Chikkamenahalli Lakshminarayana Lakshmikanth; Shancy Petsel Jacob; Vyala Hanumanthareddy Chaithra; Hugo Caire de Castro-Faria-Neto; Gopal Kedihithlu Marathe
Journal:  Inflamm Res       Date:  2016-03-19       Impact factor: 4.575

6.  Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.

Authors:  Christiane Drechsler; Salim S Hayek; Changli Wei; Sanja Sever; Bernd Genser; Vera Krane; Andreas Meinitzer; Winfried März; Christoph Wanner; Jochen Reiser
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-11       Impact factor: 8.237

7.  Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.

Authors:  Muhammad S El-Mekkawy; Nagwan Y Saleh; Ahmed A Sonbol
Journal:  Indian J Pediatr       Date:  2016-03-10       Impact factor: 1.967

Review 8.  [Use of biomarkers in sepsis. Update and perspectives].

Authors:  B H Siegler; S Weiterer; C Lichtenstern; D Stumpp; T Brenner; S Hofer; M A Weigand; F Uhle
Journal:  Anaesthesist       Date:  2014-09       Impact factor: 1.041

9.  Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood.

Authors:  Line Jee Hartmann Rasmussen; Terrie E Moffitt; Jesper Eugen-Olsen; Daniel W Belsky; Andrea Danese; HonaLee Harrington; Renate M Houts; Richie Poulton; Karen Sugden; Benjamin Williams; Avshalom Caspi
Journal:  J Child Psychol Psychiatry       Date:  2018-05-09       Impact factor: 8.982

10.  Can soluble urokinase plasminogen receptor predict outcomes after cardiac surgery?

Authors:  Chase T Schultz-Swarthfigure; Philip McCall; Robert Docking; Helen F Galley; Benjamin Shelley
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.